A case of acute profound thromb ocytopenia following abciximab therapy

Bleeding and thrombocytopenia are important adverse effects of abciximab. The incidence of abciximab-induced acute profound thrombocytopenia(APT) is low. APT is defined as an abrupt drop in platelet count to $g/min) during primary coronary angioplasty. We report a case of APT that was recognized at 2hours after the initiation of abciximab infusion and was corrected without serious complications.